Please login to the form below

Not currently logged in
Email:
Password:

Stewart Sharpe appointed VP commercial operations at Circassia

Will lead launch plans for biopharma’s first product

UK-based biopharma Circassia has appointed pharma veteran Stewart Sharpe as its first VP of commercial operations.

He will lead Circassia's commercialisation for its lead allergy treatment ToleroMune, which is due to begin phase III testing by the end of 2012.

“We believe our ToleroMune technology has the potential to revolutionise allergy treatment,” said Steve Harris, Circassia's CEO. “As we move our lead programme into the final phase of development it is the ideal time to ramp up the extensive commercial preparations required for the successful international launch of our first product.

“Stewart brings to Circassia the senior-level experience and track record of achievement needed to help us achieve this ambitious goal.”

Sharpe joins Circassia from Astellas Pharma's OSI / Prosidion subsidiary, where he was head of commercial and business development.

Previously, he held senior leadership roles at Takeda, Johnson & Johnson, Novartis, Roche and Glaxo Wellcome.

His prior commercial efforts include leading the global launch of allergy treatment Xolair (omalizumab) for Novartis.

In addition, Sharpe is a member of the board of the Oxford Biosciences Network, a member of the UK Biotechnology Industry Association (BIA) and a member of the Chartered Institute of Marketing (CIM).

21st September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics